Organic Acids
Medchemexpress LLC MRTX-EX185 formic | 2988148-70-3 | 97.23% | C34H35FN6O4 | 1 ML
MRTX-EX185 formic is a potent KRAS (G12D) inhibitor with an IC50 of 90 nM. It binds to both GDP-loaded and active GNP states of KRAS and KRAS (G12D). This compound exhibits broad-spectrum binding properties and can be utilized for studying various RAS-driven tumors, such as pancreatic cancer.
- Suppresses cell proliferation in KRAS (G12D)-driven SW-1990 pancreatic cancer cells with an IC50 of 70 nM.
- Non-toxic to non-KRAS-dependent cell lines (HEK293 cells).
- Significantly inhibits ERK phosphorylation (p-ERK) in KRAS(G12C)-driven cell lineages.
Medchemexpress LLC SJ1008030 formic | 97.7% | 919.96 | 5 MG
SJ1008030 formic is a JAK2 PROTAC that selectively degrades JAK2. It inhibits MHH-CALL-4 cell growth with an IC50 of 5.4 nM and can be used for leukemia research.
- Selectively degrades JAK2.
- Inhibits MHH-CALL-4 cell growth with an IC50 of 5.4 nM.
- Degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner.
- Dose-dependently degrades JAK2 and GSPT1 protein in xenograft bone marrow SJBALL021415 cells.
- Indicates inhibition of the JAK-STAT signaling pathway.
- Suitable for leukemia research.
Medchemexpress LLC OAB-14 | 2140911-49-3 | 99.2% | 518.73 | 1 ML
OAB-14 is a derivative of Bexarotene that improves Alzheimer's disease-related pathologies and cognitive impairments. It works by increasing β-amyloid clearance and ameliorating the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice. OAB-14 has no significant effect on body weight or liver toxicity after acute and chronic treatment.
- Improves Alzheimer's disease-related pathologies and cognitive impairments
- Increases β-amyloid clearance
- Ameliorates dysfunction of the endosomal-autophagic-lysosomal pathway
- Promotes microglia phagocytosis
- Attenuates downstream pathological events of Aβ accumulation
- Restores autophagy flux via the AMPK/mTOR pathway
- Enhances lysosomal activity and reduces Aβ accumulation in lysosomes
eMolecules 64-18-6 | Formic Acid, ACS Grade | Oakwood Chemical | MFCD00003297 | 46.025 | CH2O2 | 88.000 | OC=O | 1kg | 736631842
Formic Acid, ACS Grade | Oakwood Chemical | 64-18-6 | MFCD00003297 | 46.025 | CH2O2 | 88.000 | OC=O | 1kg | 736631842
Medchemexpress LLC CBI1 formic | 461.40 | 50 MG
CBI1 formic is a covalent BAX inhibitor that selectively derivatizes BAX at C126. It inhibits BAX activation by triggering ligands or point mutagenesis, and also blocks t-2-hex lipidation and oligomerization of BAX. CBI1 formic is effective in inhibiting BAX activation induced by BH3 ligands, F116A mutagenesis or t-2-hex.
- Covalent BAX inhibitor
- Selectively derivatizes BAX at C126
- Inhibits BAX activation by triggering ligands or point mutagenesis
- Blocks t-2-hex lipidation and oligomerization of BAX
- Inhibits BAX activation induced by BH3 ligands, F116A mutagenesis or t-2-hex
- Available in 50 mg quantity
Medchemexpress LLC LCC-12 (formic) | 3029253-76-4 | 99.9% | 460.57 | 1 MG
LCC-12 formic is a dimer of metformin that targets mitochondrial copper(II), leading to a decrease in the NAD(H) pool and modulation of inflammatory responses. It reduces inflammation in mouse models of bacterial and viral infections and serves as a tool for investigating metabolic diseases through its effects on cell plasticity and epigenetic programming.
- Targets mitochondrial copper(II)
- Leads to a decrease in the NAD(H) pool
- Modulates inflammatory responses
- Reduces inflammation in mouse models of bacterial and viral infections
- Serves as a tool for investigating metabolic diseases
- Affects cell plasticity and epigenetic programming
eMolecules 64-18-6 | Formic Acid, water less than 1% by KF | Oakwood Chemical | MFCD00003297 | 46.025 | CH2O2 | 88.000 | OC=O | 4kg | 845735967
Formic Acid, water less than 1% by KF | Oakwood Chemical | 64-18-6 | MFCD00003297 | 46.025 | CH2O2 | 88.000 | OC=O | 4kg | 845735967
Medchemexpress LLC Formic acid ammonium salt | 540-69-2 | MFCD00013103 | 98.5% | 63.06 | CH5NO2 | 1mL
Formic acid ammonium salt is an endogenous metabolite
Medchemexpress LLC Zelavespib formic (PU-H71) | 00-00-0 | 97.4% | 558.39 g/mol | C19H23IN6O4S | 5 MG
Zelavespib formic is a research-grade small-molecule inhibitor of heat shock protein 90 (Hsp90), supplied as a formic acid salt for laboratory studies. It is intended for in vitro and preclinical research use only.
- Potent Hsp90 inhibitor (IC50 51 nM in MDA-MB-468 cells).
- Formic acid salt suitable for biological assays.
- Available as solid and as a 10 mM solution in DMSO.
- High purity (97.39%).
- Molecular weight 558.39 g/mol; formula C19H23IN6O4S.
- For research use only; not for human or clinical use.
Medchemexpress LLC CBI1 formic | 461.40 | 25 MG
CBI1 formic is a covalent BAX inhibitor. It selectively derivatizes BAX at C126 and inhibits BAX activation induced by triggering ligands or point mutagenesis. CBI1 formic also blocks t-2-hex lipidation and oligomerization of BAX.
- Covalent BAX inhibitor.
- Selectively derivatizes BAX at C126.
- Inhibits BAX activation by triggering ligands or point mutagenesis.
- Blocks t-2-hex lipidation and oligomerization of BAX.
- Inhibits BAX activation induced by BH3 ligands, F116A mutagenesis, or t-2-hex.
Medchemexpress LLC Zelavespib formic | 97.4% | 558.39 | 25 MG
Zelavespib formic (PU-H71 formic) is a potent Hsp90 inhibitor with an IC50 value of 51 nM for Hsp90 in MDA-MB-468 cells. It is intended for research use only.
- Potent Hsp90 inhibitor
- Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO
- Available in various solid forms (5 mg, 10 mg, 25 mg, 50 mg, 100 mg)
- Also available in solution form (10 mM * 1 mL in DMSO)
- Cited in 12 publications
- Related to various compound screening libraries and small molecules
- Clinical trials listed for Metastatic Breast Cancer, Accelerated Phase MPN, Blast Phase MPN, Metastatic Solid Tumor, Lymphoma, Myeloproliferative Neoplasms (MPN), Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)